• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

CDK4-IN-1

(CAS: 2201897-02-9)

Suppliers of CDK4-IN-1

Company Name Email Tel Country
AMEDCHEM [email protected] +862168061059 CHINA

Fax: Purity: Brand:

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:
Remarks:
 

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of CDK4-IN-1

CDK4-IN-1 (Compound 5b) is a CDK4 inhibitor with an IC50 of 26 nM. CDK4 forms a complex with cyclinD1, which is an important component of cell cycle activation and controls the key progression step, G1 phase, where cells grow and synthesize proteins in preparation for DNA synthesis.

Solubility of CDK4-IN-1

Solubility Sources

Storage Condition of CDK4-IN-1

Storage Condition Sources

MSDS Information

MSDS Sources

Quality Control and Spectral Data

QC Reports Sources

Mechanism and Indications

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase

Chemical Information

M.Wt Formula CAS No. Synonyms
534.65 C29H38N6O4 2201897-02-9 Compound 5b

Structure Information of CDK4-IN-1

Smiles C(OC)(=O)CCCCCCC(NC1=CC=CC(NC2=NC=C3C=C(C(=O)N(C)C)N(C4CCCC4)C3=N2)=C1)=O
InChI InChI=1S/C29H38N6O4/c1-34(2)28(38)24-17-20-19-30-29(33-27(20)35(24)23-13-8-9-14-23)32-22-12-10-11-21(18-22)31-25(36)15-6-4-5-7-16-26(37)39-3/h10-12,17-19,23H,4-9,13-16H2,1-3H3,(H,31,36)(H,30,32,33)

Related Products

Other Form Products of CDK4-IN-1

Name CAS Formula Suppliers

Recommended Products in Same Target

Name CAS Formula Suppliers
LY2857785 1619903-54-6 C26H36N6O 12
THZ2 1604810-84-5 C31H28ClN7O2 10
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 22
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 5
ML167 1285702-20-6 C19H17N3O3 15
AMG 925 1401033-86-0 C26H29N7O2 15
LDC000067 1073485-20-7 C18H18N4O3S 11
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 8
LEE011 (succinate) 1374639-75-4 C27H36N8O5 9
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 8
LEE011 1211441-98-3 C23H30N8O 21
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 6
Wogonin 632-85-9 C16H12O5 28
1-NM-PP1 221244-14-0 C20H21N5 17
WHI-P180 211555-08-7 C16H15N3O3 13
THZ1 1604810-83-4 C31H28ClN7O2 18
Senexin A 1366002-50-7 C17H14N4 8
CDK4-IN-1 1256963-02-6 C22H29ClN8 9
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 16
Purvalanol B 212844-54-7 C20H25ClN6O3 22

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:

Reference

[1].Li Y, et al. Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer. J Med Chem. 2018 Apr 12;61(7):3166-3192.
A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d] pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide (6e) was discovered. The lead compound 6e with excellent CDK4/9 and HDAC1 inhibitory activity of IC50 = 8.8, 12, and 2.2 nM, respectively, can effectively induce apoptosis of cancer cell lines. The kinase profiling of compound 6e showed excellent selectivity and specificity. Compound 6e induces G2/M arrest in high concentration and G0/G1 arrest in low concentration to prevent the proliferation and differentiation of cancer cells. Mice bared-breast cancer treated with 6e showed significant antitumor efficacy. The insight into mechanisms of 6e indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53. Our data demonstrated the novel compound 6e could be a promising drug candidate for cancer therapy.

Tags: buy CDK4-IN-1 | CDK4-IN-1 IC50 | CDK4-IN-1 price | CDK4-IN-1 cost | CDK4-IN-1 solubility | CDK4-IN-1 purchase | CDK4-IN-1 manufacturer | CDK4-IN-1 research buy | CDK4-IN-1 order | CDK4-IN-1 MSDS | CDK4-IN-1 chemical structure | CDK4-IN-1 Storage condition | CDK4-IN-1 molecular weight | CDK4-IN-1 mw | CDK4-IN-1 datasheet | CDK4-IN-1 supplier | CDK4-IN-1 cell line | CDK4-IN-1 NMR | CDK4-IN-1 MS | CDK4-IN-1 IR | CDK4-IN-1 solubility | CDK4-IN-1 Safe information | CDK4-IN-1 Qc and Spectral Information | CDK4-IN-1 Clinical Information | CDK4-IN-1 Clinical Trial | CDK4-IN-1 Route of Synthesis | CDK4-IN-1 storage condition | CDK4-IN-1 diseases and conditions | CDK4-IN-1 flash point | CDK4-IN-1 boiling point | CDK4-IN-1 melting point | CDK4-IN-1 storage condition | CDK4-IN-1 brand